Choose a compound to investigate

4th Generation Anthracycline Therapy
(CNDO101 [5-imino-13-deoxydoxorubicin])

Background
Anthracyclines such as doxorubicin are used to treat many hematologic and epithelial cancers. Anthracyclines work by inhibiting topoisomerase II, a DNA-protein complex.

Doxorubicin is the most widely used chemotherapy drug due to its success in treating breast cancer, non-Hodgkins lymphoma (NHL), multiple myeloma, and pediatric acute lymphoblastic leukemia.

However, anthracyclines in general have been associated with dose related cardiotoxicity. This safety concern and the need to limit a patient’s exposure to doxorubicin has hampered the ability of oncologists to utilize these powerful agents to their patients’ benefits.

Application
CNDO101, Coronado Bioscience’s next-generation anthracycline therapy, is designed to improve the safety of anthracycline use without compromising efficacy. Doxorubicin cardiotoxicity—a critical, dose-limiting complication of therapy—appears to be caused by two structural elements that are common to the anthracycline molecule: the C5 quinone and the C13 carbonyl.

CNDO101 has been rationally designed to remove these two structural elements. The new compound, 5-imino-13-deoxydoxorubicin, appears to eliminate toxicity while maintaining the positive benefits of anthracyclines.

Preclinical studies of CNDO101 have demonstrated that the product candidate does not result in cardiotoxicity yet remains a potent anti-cancer agent. Ideally, CNDO101 will easily complement existing chemotherapy options by either replacing doxorubicin in established treatment protocols or expanding the use of anthracyclines to tumors where cardiotoxicity limits use.

CNDO101 is currently in Phase I trials and is the most advanced of Coronado Biosciences’ development compounds.